A placebo-treated patient, who discontinued therapy because of idiopathic hepatitis, was unblinded because a primary care physician advised beginning lipid-reducing treatment. Another participant was unblinded when he developed study drug–related Stevens-Johnson syndrome after approximately 9 months of ...